Share
Services
What does it truly mean to live with a chronic illness? Beyond medical symptoms, patients face daily challenges that impact their routines, emotions, and interactions with the healthcare system. To foster a deeper understanding of these realities, Fresenius Kabi is participating in an immersive patient experience program, allowing colleagues to step into the world of those they serve.
(Published: July 2025)
Employees partake in a simulation that replicates certain situations in the life of a patient. Using a dedicated app, they receive instructions and updates, engage in role-play calls with actors portraying caregivers and healthcare professionals, and interact with physical materials received in advance to go through practical aspects of managing symptoms. For 24 hours, they are not just employees working in healthcare. They become patients. This hands-on experience provides valuable insights – not only into the physical symptoms of a disease but also into the emotional and logistical burdens that come with managing a chronic condition.
To bring this immersive experience to life, Fresenius Kabi is partnering with A Life in a Day, an award-winning program designed to offer a realistic glimpse into the daily challenges of living with a chronic illness. Developed in close collaboration with patients, patient support organizations, and healthcare professionals, the program ensures accuracy and authenticity.
For our people, it has already made a lasting impression. In the most recent wave of the program, colleagues took part in the Crohn’s disease simulation, a condition that causes chronic inflammation of the gastrointestinal tract. Crohn’s can lead to severe abdominal pain, diarrhea, fatigue, and weight loss, but its impact extends beyond physical symptoms. Patients must navigate complex treatment regimens, frequent medical appointments, and the unpredictability of flare-ups which can lead to distressing situations and difficult choices about daily activities – all while balancing everyday life. Through this experience, participants gained a first-hand perspective on these challenges, strengthening their understanding of patient needs and the full burden of their disease.
This initiative aligns closely with the Fresenius principles, particularly our commitment to patient-centric care. It reminds us that healthcare is, at its core, human to human.
By fostering deeper empathy and insight, it empowers colleagues to serve patients beyond expectations and develop solutions that truly address their daily struggles. Whether in direct patient care or the development of innovative therapies, understanding the patient perspective is essential to improving healthcare. Committed to Life, the Fresenius promise, reflects this belief.
Worldwide
How Fresenius Kabi is using immersive simulations to deepen understanding of chronic illness.
Worldwide
This year marks a major milestone in our company’s history: the 50th anniversary of Fresubin®. What began as a clinical solution in 1975 has grown into a trusted and comprehensive enteral nutrition product brand for patients around the world.
Worldwide
With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine.
Worldwide
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
Germany
Our Sustainability Advisory Board got together for the first meeting of this year at Fresenius Kabi’s production and logistics site in Friedberg.
Worldwide
They serve patients beyond expectations and always give their best – not just in the fight against cancer, but also when striving for the highest possible quality of life.
Worldwide
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
Germany
Professor Dr. Michael Untch from Helios Hospital Berlin-Buch explains how the new antibody-drug conjugates (ADCs) are changing the fight against cancer.
USA
Read our interview with Chris Wegener, to find out more about the device development for CAR-T cell therapy at Fresenius Kabi.
Germany
How Fresenius Kabi is revolutionizing the treatment of cancer patients with the help of the Lovo and Cue cell processing systems.
Germany
Helios Hospital Berlin-Buch is one of the first hospitals in Germany to use augmented reality in the operating room.
Europe
By supporting the renowned museum foundation, the healthcare company demonstrates its social responsibility. The partnership is at the same time a clear commitment to Frankfurt and the Rhine-Main region.
Germany
Read our interview to find out what Dr. Anna Ossami Saidy, a doctor in training at the Helios Clinic Berlin-Buch, is currently researching.
Deutschland
#FutureFresenius is making the company fit for the future. And the brand identity must reflect and support this.
Germany
How artificial intelligence helps to detect polyps that can’t be seen by the human eye
Germany
“Personalized tumor medicine can be more effective at fighting tumors and produce beneficial therapies with fewer side effects.”
Germany
Get to know more about how this year started for Michael Sen, his view on trends like AI in health care and health equity.
Germany
Hendrik Otto and Verena Kaiser from Helios explain the benefits of changing your diet
Europe
Quirónsalud focuses on digitalisation to improve oncology patient care
Germany
Interview with Prof. Iwasaki, winner of the Else Kröner Fresenius Prize for Medical Research 2023, endowed with 2.5 million euros.
Germany
Anesthetic gas recycling reduces greenhouse gas emissions by 90 percent
Latin America
Fresenius Kabi Employees in the Dominican Republic are working to create a healthier environment.
Europe
Dr. Veronika Wolter is the first deaf person in Germany to achieve the position of chief physician. She herself uses a hearing prosthesis, and understands her patients very well.
Europe
Fresenius Helios uses the latest robotic technology to make surgery gentler for patients – for example at Helios Hospital Erfurt in Germany.
Europe
How two brave adventurers from Switzerland are exploring the world step-by-step.
Europe
As a leading global healthcare group we are dedicated to medicine and human health - values we have upheld since our founding as a pharmacy lab in 1912.
Nutrition is a topic that surrounds us every day. While we often talk about obesity and weight loss diets, we actually overlook that the opposite, meaning malnutrition or undernutrition, can be as detrimental. We speak of malnutrition when the body is not provided with enough nutrients, such as protein, carbohydrates, fats, vitamins, and minerals, which are essential for maintaining all vital body functions.
When our nutritional status is not optimal, the body becomes less resilient in facing challenges like illness, colds, or infections. Improving our nutritional status will therefore support and protect our body.
This year marks the 50th anniversary of Fresubin®, Fresenius Kabi’s trusted enteral nutrition brand. Since 1975, Fresubin® has supported over 300 million people in more than 75 countries, helping patients with their dietary management and therefore connection to life when everyday nourishment becomes a challenge.
From chronic disease and critical illness to aging, cancer care, and rehabilitation, Fresubin® has played a vital role in restoring nutritional support. Because when eating becomes difficult or impossible, nutrition is no longer just fuel. It becomes a foundation of patients’ life.
Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.
This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.
Conexxence®(1) and Bomyntra®(2) are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.
Read the full press release here.
Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.
This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.
Conexxence®(1) and Bomyntra®(2) are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.
Read the full press release here.
Discover why investing in Fresenius means investing in long-term healthcare innovation. Fresenius is a relevant, system-critical healthcare company. We combine innovative medicine, advanced medical technology, and the highest quality in clinical care to shape next-level therapies.
Watch the video for a quick summary of the key reasons to invest in Fresenius.
Listen to Elisabeth Truckenbrodt, Director of Investor Relations at Fresenius, as she shares her thoughts on the Q3/2025 results and feedback from the capital market.
Across our therapy platforms, we deliver real impact for patients, professionals, and hospitals around the world. At the same time, we create long-term value for our shareholders.
Explore below a detailed overview of why Fresenius is both – a system-critical healthcare provider and a well-positioned company.
Global healthcare systems are facing critical challenges:
Fresenius is part of the solution: We are actively addressing these global gaps by:
Our unique strength lies in the strong balance between two system-critical businesses: Fresenius Kabi and Fresenius Helios:
Both businesses hold leading market positions in attractive segments and are set for strong, sustainable organic growth and margin expansion.
In October 2022, Fresenius launched its #FutureFresenius strategy. Since then, we have made significant financial and structural progress, making our company more focused, adaptive, and performance driven.
All key financial metrics in Full-Year 2024 compared to Full-Year 2022 improved – a clear sign that our strategy is working.
Visit our Fresenius Annual Report 2024 for more information.
Persistent macroeconomic volatility and emerging geopolitical tensions, Fresenius delivers consistent performance. This reflects the operating strength and continued execution of #FutureFresenius. While serving global markets, we foster a strong local presence. This way we are able to act quickly – also in uncertainties:
We kicked-off the next phase of #FutureFresenius – Rejuvenate – in 2025: Taking our performance to the next level!
Together they offer strong potential for future growth, innovation and digitalization and thus elevating performance.
Fresenius has transformed into a more focused, performance-driven organization with a strong culture of accountability. Our mission stand firm: to save and improve human lives with affordable, accessible, and innovative healthcare products and the highest quality in clinical care.
With over 100 years of experience, Fresenius has grown from a small business into a global healthcare company. Through #FutureFresenius, we’ve become simpler, more adaptive, and more competitive - delivering real impact to patients, caregivers, hospitals, employees, and shareholders alike. We are ready to lead and remain an employer of choice in today’s competitive healthcare landscape.
Contact
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
July 22, 2025
virtual
Fresenius Sustainability Highlights Magazin 2024
